Genfit SA represents several core values and a strong corporate philosophy. The company prioritizes innovation and strives to develop groundbreaking solutions in the field of liver and metabolic diseases. Genfit SA is committed to patient-centric research and aims to improve the lives of individuals suffering from these ailments. With a focus on scientific excellence and commitment to ethical practices, Genfit SA believes in fostering collaborations and partnerships to drive progress. By combining cutting-edge research and a patient-oriented approach, Genfit SA aims to become a leading global biopharmaceutical company in its targeted therapeutic areas.

Genfit SA is primarily present in various countries and regions. The company operates not only in its home country, France, but also has a significant presence in the United States. Genfit SA also has a growing presence in other parts of the world, including Europe and Asia. This global expansion allows the company to reach a wider market and tap into diverse patient populations. With its increasing footprint, Genfit SA is well-positioned to cater to the needs of patients and healthcare providers in different countries and regions, driving its growth and success.

Genfit SA, a leading biopharmaceutical company, has achieved numerous significant milestones. Notably, the company successfully completed Phase 3 clinical trials for its investigational drug, elafibranor, in patients with nonalcoholic steatohepatitis (NASH). This milestone is remarkable as it demonstrated the drug's potential in treating a widespread liver disease with no approved therapies. Genfit SA also received Breakthrough Therapy designation from the FDA, highlighting the drug's promising efficacy and safety profile. Moreover, the company has established strong collaborations, such as the strategic alliance with LabCorp, to advance the diagnosis and treatment of NASH. Genfit SA continues to forge ahead in its mission to address significant unmet medical needs and improve patient outcomes.

Genfit SA is a renowned biopharmaceutical company based in France. Established in 1999, Genfit specializes in the development of innovative therapeutic and diagnostic solutions to address metabolic, inflammatory, and liver diseases. With a strong focus on pioneering research and advanced clinical trials, Genfit has positioned itself as a leading player in the pharmaceutical industry. The company's primary mission is to improve patient outcomes by combating diseases that represent significant medical and social challenges. Genfit SA continually strives to create value for its stakeholders through its commitment to scientific excellence, strategic collaborations, and dedication to addressing unmet medical needs.

The main competitors of Genfit SA in the market are Intercept Pharmaceuticals, Inc., Viking Therapeutics, Inc., and Madrigal Pharmaceuticals, Inc.

Genfit SA is primarily active in the pharmaceutical and biotechnology industries.

Genfit SA's business model focuses on developing and commercializing innovative therapeutic solutions for patients with metabolic and liver-related diseases. The company primarily specializes in non-alcoholic steatohepatitis (NASH), which is a progressive disease of the liver. Genfit SA's business strategy involves conducting research and development activities, clinical trials, and obtaining regulatory approvals. By creating a pipeline of potential drug candidates, Genfit SA aims to address the unmet medical needs of individuals suffering from NASH and related conditions. The company's ultimate goal is to provide effective treatment options and improve the overall quality of life for patients in this specific market.

De Genfit K/W is 11,89.

De Genfit KUV is 3,04.

De AlleAktien Kwaliteitsscore voor Genfit is 5/10.

De verwachte Genfit omzet is 88,08 mln. EUR.

De verwachte Genfit winst is 22,52 mln. EUR.

Genfit SA is a French biotech company focused on the development and commercialization of therapies for the treatment of metabolic diseases. The company is listed on the Euronext stock exchange in Paris and also has a branch in the US. Genfit SA utilizes an integrated business model that focuses on three main activities: research and development, diagnostics, and therapeutics.

Genfit keert een dividend van 0 EUR uit, verdeeld over betalingen per jaar.

De dividend kan momenteel niet worden berekend voor Genfit of het bedrijf keert geen dividend uit.

De ISIN van Genfit is FR0004163111.

Het WKN van Genfit is A0LGJ2.

De ticker van Genfit is GNFT.PA.

Binnen de laatste 12 maanden betaalde Genfit een dividend van . Dit komt overeen met een dividendrendement van ongeveer . Voor de komende 12 maanden zal Genfit naar verwachting een dividend van 0 EUR betalen.

De dividendrendement van Genfit is momenteel .

Genfit betaalt elk kwartaal een dividend uit. Dit wordt uitgekeerd in de maanden .

Genfit betaalde de afgelopen 0 jaar elk jaar dividend.

Voor de komende 12 maanden wordt een dividend van 0 EUR verwacht. Dit komt overeen met een dividendrendement van 0 %.

Genfit wordt toegewezen aan de sector 'Gezondheid'.

Om het laatste dividend van Genfit van 5-11-2024 ter hoogte van 0 EUR te ontvangen, moest je het aandeel voor de ex-datum op 5-11-2024 in je portefeuille hebben.

De laatste dividenduitkering vond plaats op 5-11-2024.

In het jaar 2023 heeft Genfit 0 EUR aan dividenden uitgekeerd.

De dividenden van Genfit worden in EUR uitgekeerd.